4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution [Seeking Alpha]
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: Seeking Alpha
The company's pipeline includes promising ophthalmology, pulmonology, and cardiology candidates, with Phase 3 progress for wet AMD and cystic fibrosis treatments. FDMT's platform allows for quickly creating custom viral vectors tailored to specific diseases, setting it apart from competitors. FDMT's recent public offering bolsters its position and extends its cash runway to 5.8 years, allowing time for research and clinical trials. I believe FDMT stock is a strong buy, driven by its innovative platform and a robust pipeline with a solid cash position. 4D Molecular Therapeutics, Inc., also known as 4DMT ( NASDAQ: FDMT ), is a clinical-stage biotechnology company that leverages its Therapeutic Vector Evolution platform to innovate genetic medicine. This technology designs specialized viral vectors that are precision Recommended For You Recommended For You About FDMT Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.MarketBeat
- We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow [Yahoo! Finance]Yahoo! Finance
- 4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023) [Yahoo! Finance]Yahoo! Finance
- 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights [Yahoo! Finance]Yahoo! Finance
- 4DMT Reports First Quarter 2024 Financial Results and Operational HighlightsGlobeNewswire
FDMT
Earnings
- 5/9/24 - Beat
FDMT
Sec Filings
- 5/9/24 - Form 8-K
- 5/9/24 - Form 10-Q
- 4/18/24 - Form 4
- FDMT's page on the SEC website